Information Provided By: 
Fly News Breaks for May 21, 2019
OCUL
May 21, 2019 | 08:58 EDT
As previously reported, Raymond James downgraded Ocular Therapeutix to Outperform from Strong Buy and lowered its price target to $5 from $11 after the company reported disappointing pivotal data for the OTX-TP program. Analyst Dane Leone removed revenue estimates for OTX-TP from his model, but said the company can drive significant value from deeper pipeline projects like OTX-TKI.
News For OCUL From the Last 2 Days
